Today’s stock pick update – Open Now

Learn More

You Could Make $300 to $1100 Per Contract With This Simple Trade

Imagine getting really good at mastering just ONE simple trade. A trade that appears like clockwork between 9:30-10:45am on most trading days. This free step-by-step guide, by options expert, Dave Acquino, shows you how to spot and take these trades so you can walk away with daily profits!(Ad)

CLICK HERE for instant access.

Stocks Are Higher After Treasury Secretary Mnuchin Says He’s “Hopeful” Agreement Can Be Reached On New Stimulus Deal

Treasury Secretary Steven Mnuchin struck a “hopeful” tone on stimulus, Mnuchin said he will speak again with House Speaker Nancy Pelosi today regarding a possible deal, with an aim to reach “understanding” with Pelosi on a broad relief package by Thursday. “I say we’re going to give it one more serious try to get this done and I think we’re hopeful that we can get something done,” Mnuchin said. “I think there is a reasonable compromise here.” While House D...

Read More

Sorrento Therapeutics (NASDAQ: SRNE): Sorrento Therapeutics gained 20% yesterday after the biotech released encouraging preclinical data for its experimental COVID-19 antibody therapies STI-1499 and STI-2020. “We believe that the results for STI-1499 and STI-2020 are truly remarkable. Based on the preclinical testing we have conducted to date, STI-2020 is our most promising SARS-...

Read More

ACCO has a great value proposition – is the timing right for this stock?

It is interesting to observe the disconnect between broad stock market expectations versus the economic data that points to a much more gradual pace of economic growth. One of the places where I think that can be seen more easily is in evaluating large-cap versus small-cap stocks. Many of the biggest and most recognizable names in the market have followed the broad indices higher, and if you look at the fundamentals of many of those companies, there are clear indications that they have been a...

Read More

Sorrento Therapeutics, Inc., a clinical stage biopharma company, develops therapies for cancer, autoimmune, inflammatory, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutics by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugates, as well as b...

Read More

Already subscribed to our premium service?

Click here to Login.

Not a TradersPro subscriber yet?

Learn More About TradersPro Here - Learn The # 1 Key To Successful Stock Investing Profits

This email was sent to phanphuongthanh89.822152@blogger.com 
by TradersPro Investiv, LLC
265 N. Main | Ste. D #283
Kaysville | UT | 84037

Unsubscribe or Mange which emails you get from TradersPro
 
All trading carries significant risk. Please see our full risk disclaimer.


Disclaimers, Terms & Conditions | Privacy Policy

Copyright © 2020

 

No comments:

Post a Comment